Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL

Arthritis and Rheumatology

Volumn 69, Issue 1, 2017, Pages 122-130

  Gordon, Caroline ^a   Wofsy, David ^b   Wax, Stephen ^c   Li, Yong ^c   Pena Rossi, Claudia ^d   Isenberg, David ^e  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMD Serono   (United States)

^d MERCK SERONO S A   (Switzerland)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; DOUBLE STRANDED DNA; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISONE; HYBRID PROTEIN; TACI RECEPTOR-IGG FC FRAGMENT FUSION PROTEIN; TNFSF13B PROTEIN, HUMAN;

ACUTE RESPIRATORY FAILURE; ADULT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INFECTION RATE; LEPTOSPIROSIS; LUNG HEMORRHAGE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMA CELL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

B-CELL ACTIVATING FACTOR; BIOMARKERS; DOUBLE-BLIND METHOD; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 85006100786     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39809     Document Type: Article

References (27)

1. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014;384:1878–88.
2. Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 2009;18:869–74.
3. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550–7.
4. Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008;35:2152–8.
5. Dobkin PL, da Costa D, Fortin PR, Edworthy S, Barr S, Esdaile JM, et al. Living with lupus: a prospective pan-Canadian study. J Rheumatol 2001;28:2442–8.
6. Mazzoni D, Cicognani E. Social support and health in patients with systemic lupus erythematosus: a literature review. Lupus 2011;20:1117–25.
7. Arnaud L, Mathian A, Boddaert J, Amoura Z. Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment. Drugs Aging 2012;29:181–9.
8. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 2012;14 Suppl 4:S4.
9. Postal M, Costallat LT, Appenzeller S. Biological therapy in systemic lupus erythematosus. Int J Rheumatol 2012;2012:578641.
10. Tieng AT, Peeva E. B cell-directed therapies in systemic lupus erythematosus. Semin Arthritis Rheum 2008;38:218–27.
11. Liossis SN, Melissaropoulos K. Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments. Expert Opin Pharmacother 2014;15:833–40.
12. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006;5:235–46.
13. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168–78.
14. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142–50.
15. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065–7.
16. Matthes T, Dunand-Sauthier I, Santiago-Raber ML, Krause KH, Donze O, Passweg J, et al. Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood 2011;118:1838–44.
17. Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003;112:286–97.
18. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004;199:1577–84.
19. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169:4314–21.
20. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050:34–9.
21. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2015;74:2006–15.
22. Isenberg DA, Gordon C, British Isles Lupus Assessment Group. From BILAG to BLIPS: disease activity assessment in lupus past, present and future. Lupus 2000;9:651–4.
23. Boghdadi G, Elewa EA. Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Rheumatol Int 2014;34:1217–23.
24. McCarthy EM, Lee RZ, Ni Gabhann J, Smith S, Cunnane G, Doran MF, et al. Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort. Rheumatology (Oxford) 2013;52:1279–84.
25. Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013;65:2143–53.
26. Yee CS, Su L, Toescu V, Hickman R, Situnayake D, Bowman S, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford) 2015;54:836–43.
27. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269–74.